| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Human Endogenous Metabolite; SIRT3; SIRT1
|
|---|---|
| ln Vitro |
Nicotinamide riboside tartrate (0.5 nM; 24 hours) decreases Ndufa9 and SOD2's acetylation status[1].
Nicotinamide riboside tartrate increases the intracellular and mitochondrial NAD+ content in C2C12, Hepa1.6, and HEK293 cells in a concentration-dependent manner at concentrations ranging from 1-1000 μM[1]. Nicotinamide riboside tartrate increases NAD to support innate immunity against coronaviruses (CoVs), the source of COVID-19, by restoring antiviral poly(ADP-ribose) polymerase (PARP) functions[3]. |
| ln Vivo |
Chronic Nicotinamide riboside tartrate (p.o.; 400 mg/kg/day; for 16 weeks) supplementation raises plasma and intracellular NAD+ content in a tissue-specific manner[1].
|
| Cell Assay |
Cell Line: HEK293T cells
Concentration: 0.5 nM Incubation Time: 24 hours Result: Reduced the acetylation status of Ndufa9 and SOD2. |
| Animal Protocol |
10-week-old C57Bl/6J mice
400 mg/kg PO; daily; for 16 weeks |
| References |
|
| Molecular Formula |
C15H20N2O11
|
|---|---|
| Exact Mass |
404.11
|
| CAS # |
2415657-86-0
|
| Related CAS # |
Nicotinamide riboside chloride;23111-00-4;Nicotinamide riboside;1341-23-7;Nicotinamide riboside malate;2415659-01-5
|
| PubChem CID |
146673020
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
460
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O
|
| InChi Key |
TXLSDIXNZRLFCH-ZRDCEPLESA-N
|
| InChi Code |
InChI=1S/C11H14N2O5.C4H6O6/c12-10(17)6-2-1-3-13(4-6)11-9(16)8(15)7(5-14)18-11;5-1(3(7)8)2(6)4(9)10/h1-4,7-9,11,14-16H,5H2,(H-,12,17);1-2,5-6H,(H,7,8)
|
| Chemical Name |
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide;(2R,3R)-2,3,4-trihydroxy-4-oxobutanoate
|
| Synonyms |
Nicotinamide riboside tartrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06018467 | Recruiting | Dietary Supplement: Nicotinamide Riboside 1g (oral) Drug: Dasatinib 100 Mg Oral Tablet |
Osteopenia, Osteoporosis | Odense University Hospital | September 6, 2023 | Phase 2 |
| NCT03818802 | Recruiting | Dietary Supplement: Nicotinamide Riboside Dietary Supplement: Placebo |
Healthy Elderly Volunteers | Mayo Clinic | September 16, 2019 | Not Applicable |
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
